Dihydroergotoxine Methanesulphonate
Dihydroergotoxine Methanesulphonate Brand names, Dihydroergotoxine Methanesulphonate Analogs
- Alkergot
- Circanol
- Co-Dergocrine Mesylate
- Deapril-ST
- Dihydroergotoxin Mesilat
- Dihydroergotoxin Mesylate
- Dihydroergotoxin Methanesulfonate
- Dihydroergotoxine Mesilate
- Dihydroergotoxine Mesylate
- Dihydroergotoxine Methanesulfonate
- Dihydroergotoxine Methanesulphonate
- Ergoloid Mesylates [Usan]
- Gerimal
- Hydergin
- Hydergine
- Hydergine LC
- Hydrogenated Ergot Alkaloids
- Ischelium
- Redergin
- Trigot
Dihydroergotoxine Methanesulphonate Brand Names Mixture
- No information avaliable
Dihydroergotoxine Methanesulphonate Chemical_Formula
C33H45N5O5
Dihydroergotoxine Methanesulphonate RX_link
No information avaliable
Dihydroergotoxine Methanesulphonate fda sheet
Dihydroergotoxine Methanesulphonate msds (material safety sheet)
Dihydroergotoxine Methanesulphonate Synthesis Reference
No information avaliable
Dihydroergotoxine Methanesulphonate Molecular Weight
591.741 g/mol
Dihydroergotoxine Methanesulphonate Melting Point
No information avaliable
Dihydroergotoxine Methanesulphonate H2O Solubility
No information avaliable
Dihydroergotoxine Methanesulphonate State
Solid
Dihydroergotoxine Methanesulphonate LogP
2.615
Dihydroergotoxine Methanesulphonate Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Dihydroergotoxine Methanesulphonate Indication
For use as an adjunct therapy for patients with dementia
Dihydroergotoxine Methanesulphonate Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Dihydroergotoxine Methanesulphonate Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Dihydroergotoxine Methanesulphonate side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Dihydroergotoxine Methanesulphonate Patient Information
No information avaliable
Dihydroergotoxine Methanesulphonate Organisms Affected
Humans and other mammals
